サンプル依頼リスト カート
表紙：細胞・遺伝子治療の世界市場：疾患タイプ別市場動向、開発、動向と予測（第4版）：2024年～2030年
市場調査レポート
商品コード
1712819

細胞・遺伝子治療の世界市場：疾患タイプ別市場動向、開発、動向と予測（第4版）：2024年～2030年

Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
細胞・遺伝子治療の世界市場：疾患タイプ別市場動向、開発、動向と予測（第4版）：2024年～2030年
出版日: 2025年04月25日
発行: Kalorama Information
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

当レポートは、現代医療における細胞治療と遺伝子治療の変革の可能性について調査しています。これらの治療法は、疾患の遺伝的原因に対処し、免疫系を調節することで画期的な治療を提供します。当レポートでは、腫瘍学や心臓病学など様々な治療領域で臨床試験が活発に行われている、新しい治療法の急増と有望なパイプラインを紹介しています。

また、市場を治療分野別に分類し、詳細な市場推計・予測、競合情勢に関する考察を提供する包括的なレポートです。主要製品、研究動向、市場内訳、地域別収益、競合分析に焦点を当て、細胞・遺伝子・RNA治療市場の世界の動向を網羅しています。

主な治療分野は以下の通りです：

  • 腫瘍学
  • 神経学
  • 筋骨格系
  • 皮膚科学
  • 循環器/非オンコロジー血液
  • その他

当レポートでは、COVID-19のRNA療法と感染症用mRNAワクチンは除外し、代わりに広範な遺伝子治療の適用に焦点を当てています。また、臍帯血製剤は移植としての分類を考慮し、除外しています。

調査手法としては、業界関係者へのインタビューや包括的な文献調査など、1次調査と2次調査を組み合わせています。市場のハイライト、予測、競合分析を提供し、市場指標、動向、障壁について論じています。遺伝子治療の黎明期であることから、予測は限られた先行事例に基づいており、2024年の市場規模推計・予測と2030年までの予測を掲載しています。

当レポートは、細胞治療と遺伝子治療の進化する状況を理解するための重要な資料として役立ち、ヘルスケアとバイオテクノロジー分野の利害関係者に貴重な洞察を提供します。

目次

第1章 エグゼクティブサマリー

第2章 細胞・遺伝子治療イントロダクション

  • イントロダクション
  • 細胞治療
  • 遺伝子治療
  • 細胞・遺伝子治療：特徴
  • 人材配置
  • CAR-Tの製造プロセス
  • 細胞・遺伝子治療の製造プロセス
  • 費用
  • 償還
  • ロジスティクス
  • 合併と買収
  • 取引、合意、コラボレーション
  • 規制の動向
  • パイプライン、開発概要
  • パイプライン、開発進捗
  • 疾患・治療領域別パイプライン
  • 第III相開発
  • エンドユーザー

第3章 腫瘍学における細胞・遺伝子治療市場

  • 概要
  • がんの増殖の原因
    • 環境要因、DNA、RNA
    • 細胞がん遺伝子
    • 腫瘍抑制遺伝子
  • 世界のがん負担
  • 市場見通し
  • 主な製品
  • 研究開発の動向
    • 第III相開発
  • 細胞・遺伝子治療の市場内訳
  • 地域市場サマリー
  • 競合のサマリー

第4章 神経関連疾患における細胞・遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
    • 第III相開発
  • 細胞・遺伝子治療の市場内訳
  • 地域市場サマリー
  • 競合のサマリー

第5章 筋骨格系の疾患および障害における細胞・遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
    • 第III相開発
  • 細胞・遺伝子治療の市場内訳
  • 地域市場サマリー
  • 競合のサマリー

第6章 心血管疾患および血液疾患における細胞・遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 細胞、遺伝子、RNA治療の市場内訳
  • 心血管・血液疾患の細胞・遺伝子治療市場（適応症別）
  • 地域市場サマリー
  • 競合のサマリー

第7章 皮膚科における細胞・遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
    • 第III相開発
  • 細胞・遺伝子治療の市場内訳
  • 地域市場サマリー
  • 競合のサマリー

第8章 細胞・遺伝子治療市場の状況

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
  • 細胞・遺伝子治療の市場内訳
  • 地域市場サマリー
  • 競合のサマリー

第9章 細胞・遺伝子治療市場レビュー

  • 市場の影響
  • 細胞・遺伝子治療とウイルスベクターの不足
  • 世界市場のサマリー
  • 細胞治療市場と遺伝子治療市場
  • 地域市場概要
  • 北米
  • 欧州/EU
  • その他の国
  • 細胞・遺伝子治療市場における競合ランキング

第10章 市場参入企業

  • 主要な影響力のある企業
  • AlloSource
  • Alnylam Pharmaceuticals, Inc
  • Amgen
  • AnGes Inc
  • Anterogen Co Ltd.
  • Atara Biotherapeutics
  • BioCardia
  • Biogen, Inc.
  • BioMarin Pharmaceuticals
  • bluebird bio, Inc.
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Candel Therapeutics
  • Castle Creek Biosciences
  • Celyad Oncology
  • Cook Myosite, Inc
  • Dendreon Pharmaceuticals
  • Ferring Pharmaceuticals
  • Gamida Cell Ltd.
  • GenSight Biologics S.A.
  • Gilead Sciences, Inc.
  • Gradalis, Inc
  • Helixmith
  • Inovio Pharmaceuticals, Inc
  • Medeor Therapeutics
  • MEDIPOST Co, Ltd.
  • MeiraGTx
  • Mesoblast Ltd
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • NuVasive Biologics
  • Orchard Therapeutics
  • Organogenesis
  • Orthofix
  • Osiris Therapeutics, Inc.
  • Pharmicell
  • Pluristem Therapeutics, Inc.
  • Sangamo Therapeutics
  • Sanofi
  • Sarepta Therapeutics
  • Sotio a.s.
  • Spark Therapeutics
  • uniQure N.V.
  • Vericel Corporation
目次
Product Code: 25-015KA

The "Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)" report by Kalorama Information explores the transformative potential of cell and gene therapies in modern medicine. These therapies offer groundbreaking treatments by addressing genetic causes of diseases and modulating the immune system. The report highlights the surge in new therapies and a promising pipeline, with significant clinical trial activity across various therapeutic areas, including oncology and cardiology.

This comprehensive report segments the market by therapeutic areas, providing detailed market estimates, forecasts, and insights into the competitive landscape. It covers global developments in cell, gene, and RNA therapy markets, focusing on key products, research trends, market breakdowns, regional revenues, and competitor analysis.

Key therapeutic areas covered include:

  • Oncology
  • Neurology
  • Musculoskeletal
  • Dermatology
  • Cardiology/Non-oncology blood
  • Other

The report excludes RNA therapies for COVID-19 and mRNA vaccines for infectious diseases, focusing instead on broader gene therapy applications. It also omits cord blood products, considering their classification as transplants.

Methodologically, the report combines primary and secondary research, including interviews with industry participants and comprehensive literature reviews. It provides market highlights, forecasts, and competitive analyses, discussing market indicators, trends, and barriers. Given the nascent stage of gene therapies, forecasts are based on limited precedents, with market size estimates provided for 2024 and projections through 2030.

This report serves as a crucial resource for understanding the evolving landscape of cell and gene therapies, offering valuable insights for stakeholders in the healthcare and biotechnology sectors.

Table of Contents

Chapter 1: Executive Summary

  • Overview
  • Scope and Methodology
  • Market Overview and Potential
    • Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Table 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 1-2: Global Share of Cell and Gene Therapy Market, by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 1-3: Global Share of Cell and Gene Therapy Market, by Product Segment, 2029 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]

Chapter 2: Introduction to Cell and Gene Therapy

  • Introduction
    • Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, 2022-2024, Global (count, %)
    • Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, January 2025 (%)
  • Cell Therapy
    • CAR T
    • Stem Cells
    • Adult Stem Cells
    • Human Embryonic Stem Cells
      • Table 2-2: Adult vs. Embryonic Stem Cells
  • Gene Therapy
    • Table 2-3: Somatic vs. Germ Line Gene Therapy
    • Viral Vector System and New Developments
      • Table 2-4: Selected Examples of Viruses in Gene Therapy
      • Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)
    • Non-viral Systems for Transporting Genes
    • Gene Editing
  • Cell and Gene Therapy: Characteristics
    • Table 2-5: Cell Therapy vs Gene Therapy
  • Staffing
  • Manufacturing Process for CAR-T
    • Leukapheresis
    • Activation
    • Transduction
    • Expansion
  • Cell and Gene Therapy Manufacturing Processes
    • Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
    • Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
  • Cost
  • Reimbursement
  • Logistics
  • Mergers and Acquisitions
    • Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
  • Deals, Agreements, and Collaborations
  • Regulatory Developments
    • Fast Track
    • Orphan Drug
    • Breakthrough Therapy
    • Accelerated Approval
    • Priority Review
      • Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country
    • Gene Therapy Approval Process
  • Pipeline, Development Overview
  • Pipeline, Development Progress
    • Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), 2022-2024 (Count, %)
    • Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of Q4 2024
    • Table 2-10: Global Gene Therapy Pipeline, by Phase, 2022-2024 (count, %)
    • Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q4 2024 (%)
  • Pipeline by Condition and Therapeutic Area
    • Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
    • Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area, Q4 2024 (%) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
    • Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
    • Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other]
    • Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, Share Q4 2024 (%) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa]
    • Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, NA/Unspecified]
    • Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease, 2022-2024 (count, %) [Alzheimer's disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson's disease; Respiratory distress syndrome, acute; Spinal cord injury]
    • Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin's; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne's muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington's disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia]
    • Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous]
    • Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal; Dystrophy, Duchenne's muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington's disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute]
  • Phase III Development
    • Table 2-19: Phase III Development - Cell and Gene Therapies, Select Projects
  • End Users
    • Hospitals
    • Research
    • Wound Care Centers
    • Cancer Centers

Chapter 3: Cell and Gene Therapy Markets in Oncology

  • Overview
    • Biochemistry of Cancer Cells
  • Causes of Cancer Growth
    • Environmental Factors, DNA, RNA
      • Table 3-1: Virus Association with Human Cancer
    • Cellular Oncogenes
    • Tumor Suppressor Genes
  • Global Cancer Burden
    • Figure 3-1: Estimated Number of New Cancer Cases, Both Sexes, Age 0-85+, All Cancers, 2020 to 2040
    • Figure 3-2: Incidence of Cancer, by Type, 2020 [Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid]
    • Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type, 2020 [Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers]
  • Market Outlook
    • Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)
    • Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)
  • Principal Products
    • Abecma
    • APCeden
    • Aucatzyl
    • Breyanzi
    • Carvykti
    • CreaVax-RCC
    • Delytact
    • Gendicine
    • Imlygic
    • Immuncell-LC
    • Kymriah
    • Provenge
    • Relma-cel
    • Rytelo
    • Tecartus
    • Tecelra
    • Yescarta
    • Zevor-cel
      • Table 3-3: Cell and Gene Therapy in Oncology
  • Trends in Research and Development
    • Phase III Development
      • Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2025
  • Market Breakdown of Cell and Gene Therapies
    • Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type, Estimated Sales 2024 and Projected 2030 Sales ($ million) [CAR-T, Cell Immunotherapy, Gene/Oligo/Conjugate Therapy, Other Cell]
    • Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [CAR-T, Cell Immunotherapy, Gene Therapy]
    • Oncology Cell and Gene Therapy Market by Cancer Type
      • Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type, Estimated 2024 and Projected 2030 Sales ($ million) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Undefined Blood Cancer, Other Cancers]
      • Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
      • Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
  • Regional Market Summary
    • Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
    • Figure 3-7: Oncology Cell and Gene Therapy Market, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
    • Figure 3-8: Oncology Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
  • Competitor Summary
    • Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
    • Figure 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales, Estimated 2024 ($ million) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
    • Figure 3-10: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2024 (%) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]

Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders

  • Overview
  • Market Outlook
    • Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
    • Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
  • Principal Products
    • Amvuttra
    • Libmeldy/ Lenmeldy
    • NeuroNata-R
    • Onpattro
    • SKYSONA
    • Spinraza
    • Stemirac
    • Upstaza
    • Wainua
    • Zolgensma
      • Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders
  • Trends in Research and Development
    • Phase III Development
      • Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2025
  • Market Breakdown of Cell and Gene Therapies
    • Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
    • Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2024 (%) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
  • Regional Market Summary
    • Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
    • Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
  • Competitor Summary
    • Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]
    • Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 ($ million) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]

Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

  • Overview
  • Market Outlook
    • Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
    • Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
  • Principal Products
    • AlloStem
    • Amondys
    • BIO4
    • Carticel
    • Cartiform
    • CartiLife
    • Cartistem
    • Chondron
    • Elevidys
    • Exondys
    • JACC
    • MACI
    • Ortho-ACI and Ortho-ATI
    • Ossron
    • Osteocel and Osteoplus
    • Spherox
    • Trinity Elite and Trinity Evolution
    • Vyondys
      • Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders
  • Trends in Research and Development
    • Phase III Development
      • Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2025
  • Market Breakdown of Cell and Gene Therapies
    • Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million)
    • Musculoskeletal Cell and Gene Therapy Market by Indication
      • Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others (Tendon Damage, Osteoarthritis)]
      • Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 (%) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others (Tendon Damage, Osteoarthritis)]
  • Regional Market Summary
    • Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, Estimated 2024 (%) [APAC, Europe, United States, ROW]
    • Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
    • Figure 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
  • Competitor Summary
    • Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2024 ($ million) [Sarepta, Vericel, Other Companies]
    • Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 (%) [Sarepta, Vericel, Other Companies]

Chapter 6: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

  • Overview
    • Cardiovascular Disease
    • Selected Blood Disorders
  • Market Outlook
    • Table 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
    • Figure 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
  • Principal Products
    • Collategene
    • Hearticellgram
    • HeartSheet
    • Leqvio
    • Neovasculgen
    • Stempeucel
    • Zynteglo
      • Table 6-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
    • Phase III Development
      • Table 6-3: Select Cardiovascular and Blood Disorder in Phase III Cell and Gene Therapy Developments, through January 2025
  • Market Breakdown of Cell, Gene, and RNA Therapies
    • Table 6-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
    • Figure 6-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
    • Table 6-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Blood, Cardiac, Hypercholesterolemia, Vascular]
  • Regional Market Summary
    • Table 6-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
    • Figure 6-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
    • Figure 6-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
  • Competitor Summary

Chapter 7: Cell and Gene Therapy Markets in Dermatology

  • Overview
    • Table 7-1: Wound Prevalence, by Type [Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns]
  • Market Outlook
    • Table 7-2: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
    • Figure 7-1: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
  • Principal Products
    • Adipocel
    • Apligraf
    • CureSkin
    • Dermagraft
    • Epicel
    • Grafix
    • Holoderm
    • Kaloderm
    • KeraHeal/KeraHeal-Allo
    • LaViv
    • Orcel
    • Quencell
    • RECELL
    • Rosmir
    • Stempeutics/Cutisera
    • StrataGraft
    • Stravix
    • TransCyte
    • Vyjuvek
      • Table 7-3: Cell and Gene Therapy in Dermatological Diseases and Disorders
  • Trends in Research and Development
    • Phase III Development
      • Table 7-4: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2025
  • Market Breakdown of Cell and Gene Therapies
    • Table 7-5: Dermatology Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
    • Figure 7-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
    • Dermatology Cell and Gene Therapy Market by Indication
  • Regional Market Summary
    • Table 7-6: Dermatology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 & Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
    • Figure 7-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
    • Figure 7-4: Dermatology Cell and Gene Therapy Market Share, by Geographic Region, 2024 (%) [APAC, Europe, North America, ROW]
  • Competitor Summary
    • Table 7-7: Dermatology Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]
    • Figure 7-5: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2024 (%) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]

Chapter 8: Cell and Gene Therapy Markets in Other Conditions

  • Overview
  • Market Outlook
    • Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
    • Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
  • Principal Products
    • Alofisel
    • Cupistem
    • Givlaari
    • Glybera
    • Holoclar
    • Luxturna
    • Oxlumo
    • Rethymic
    • Ryoncil/ Prochymal/ Temcell
    • Tryngolza
      • Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders
  • Trends in Research and Development
  • Market Breakdown of Cell and Gene Therapies
    • Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
    • Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
  • Regional Market Summary
    • Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
    • Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
    • Figure 8-4: Other Conditions Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [Europe, North America, ROW]
  • Competitor Summary

Chapter 9: Cell and Gene Therapy Market Review

  • Market Influences
    • Global Demographics
      • Table 9-1: Global Population, 1980-2050 (population in millions)
    • Aging Population
      • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
    • Cost Containment
      • Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies
  • Cell and Gene Therapy and Viral Vector Shortages
  • Global Market Summary
    • Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/non-oncology blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-2a: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-2b: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales by Disease Segment, 2024 [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Cell vs. Gene Therapy Markets
    • Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method, 2024-2030 ($ million)
    • Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2024 (%)
    • Figure 9-5: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2029 (%)
  • Regional Market Overview
    • Table 9-5: Cell, Gene, & RNA Therapy Market Summary by Geographical Region, 2024-2030 ($ million) [Europe, North America, ROW]
  • North America
    • Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Table 9-7: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-6: U.S. Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Table 9-8: Major Cell and Gene Therapy Product Approvals, FDA
  • Europe/European Union
    • Table 9-9: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-7: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-8: Europe Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Table 9-10: Major Cell and Gene Therapy Approvals by EMA
  • Other Countries
    • Table 9-11: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-9: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Figure 9-10: ROW Cell, Gene, & RNA Therapy Market, Distribution by Disease Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Table 9-12: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
  • Competitor Ranking in Cell and Gene Therapy Markets
    • Table 9-13: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
    • Figure 9-11: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
    • Figure 9-12: Cell and Gene Therapy Market Share Estimates by Leading Competitors, 2024 (%) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]

Chapter 10: Market Participants

  • Leading Influencers
  • AlloSource
    • Table 10-1: AlloSource Corporate Summary
    • Company Summary
    • Products
  • Alnylam Pharmaceuticals, Inc.
    • Table 10-2: Alnylam Pharmaceuticals Corporate Summary
    • Company Summary
    • Products
  • Amgen
    • Table 10-3: Amgen Corporate Summary
    • Company Summary
    • Products
  • AnGes Inc.
    • Table 10-4: AnGes Corporate Summary
    • Company Summary
    • Products
  • Anterogen Co Ltd.
    • Table 10-5: Anterogen Corporate Summary
    • Company Summary
    • Products
  • Atara Biotherapeutics
    • Table 10-6: Atara Biotherapeutics Corporate Summary
    • Company Summary
    • Products
  • BioCardia
    • Table 10-7: BioCardia Summary
    • Company Summary
    • Products
    • Projects in the pipeline using the CardiAMP system include:
    • Projects in the pipeline using the CardiALLO system include:
  • Biogen, Inc.
    • Table 10-8: Biogen Corporate Summary
    • Company Summary
    • Products
  • BioMarin Pharmaceuticals
    • Table 10-9: BioMarin Pharmaceuticals Corporate Summary
    • Company Summary
    • Products
  • bluebird bio, Inc.
    • Table 10-10: bluebird bio Corporate Summary
    • Company Summary
    • Products
  • BrainStorm Cell Therapeutics
    • Table 10-11: BrainStorm Cell Therapeutics Corporate Summary
    • Company Summary
    • Products
  • Bristol-Myers Squibb
    • Table 10-12: Bristol-Myers Squibb Corporate Summary
    • Company Summary
    • Products
  • Candel Therapeutics
    • Table 10-13: Candel Therapeutics Corporate Summary
    • Company Summary
    • Products
    • In the pipeline, the company offers:
  • Castle Creek Biosciences
    • Table 10-14: Castle Creek Corporate Summary
    • Company Summary
    • Products
  • Celyad Oncology
    • Table 10-15: Celyad Oncology Corporate Summary
    • Company Summary
    • Products
  • Cook Myosite, Inc
    • Table 10-16: Cook Myosite Corporate Summary
    • Company Summary
    • Products
  • Dendreon Pharmaceuticals (Sanpower)
    • Table 10-17: Dendreon Corporate Summary
    • Company Summary
    • Products
  • Ferring Pharmaceuticals
    • Table 10-18: FerGene Corporate Summary
    • Company Summary
    • Products
  • Gamida Cell Ltd.
    • Table 10-19: Gamida Cell Corporate Summary
    • Company Summary
    • Products
  • GenSight Biologics S.A.
    • Table 10-20: GenSight Biologics Corporate Summary
    • Company Summary
    • Products
  • Gilead Sciences, Inc.
    • Table 10-21: Gilead Sciences Corporate Summary
    • Company Summary
    • Products
  • Other selected indications in the pipeline include:
  • Gradalis, Inc
    • Table 10-22: Gradalis Corporate Summary
    • Company Summary
    • Products
  • Helixmith
    • Table 10-23: Helixmith Corporate Summary
    • Company Summary
    • Products
  • Inovio Pharmaceuticals, Inc.
    • Table 10-24: Inovio Pharmaceuticals Corporate Summary
    • Company Summary
    • Products in the Pipeline
  • Medeor Therapeutics
    • Table 10-25: Medeor Therapeutics Corporate Summary
    • Company Summary
    • Products
  • MEDIPOST Co, Ltd.
    • Table 10-26: MEDIPOST Corporate Summary
    • Company Summary
    • Products
  • MeiraGTx
    • Table 10-27: MeiraGTx Corporate Summary
    • Company Summary
    • Products
  • Mesoblast Ltd.
    • Table 10-28: Mesoblast Corporate Summary
    • Company Summary
    • Products
  • Northwest Biotherapeutics, Inc.
    • Table 10-29: Northwest Biotherapeutics Corporate Summary
    • Company Summary
    • Products
  • Novartis AG
    • Table 10-30: Novartis Corporate Summary
    • Company Summary
    • Products
    • Other Current Projects
  • NuVasive Biologics
    • Table 10-31: NuVasive Biologics Corporate Summary
    • Company Summary
    • Products
  • Orchard Therapeutics
    • Table 10-32: Orchard Therapeutics Corporate Summary
    • Company Summary
    • Products
  • Organogenesis
    • Table 10-33: Organogenesis Corporate Summary
    • Company Summary
    • Products
  • Orthofix
    • Table 10-34: Orthofix Corporate Summary
    • Company Summary
    • Products
  • Osiris Therapeutics, Inc. (Smith & Nephew)
    • Table 10-35: Osiris Corporate Summary
    • Company Summary
    • Products
  • Pharmicell
    • Table 10-36: Pharmicell Corporate Summary
    • Company Summary
    • Products
  • Pluristem Therapeutics, Inc.
    • Table 10-37: Pluristem Therapeutics Corporate Summary
    • Company Summary
    • Products
  • Sangamo Therapeutics
    • Table 10-38: Sangamo Therapeutics Corporate Summary
    • Company Summary
    • Products
  • Sanofi
    • Table 10-39: Sanofi Corporate Summary
    • Company Summary
  • Sarepta Therapeutics
    • Table 10-40: Sarepta Corporate Summary
    • Company Summary
    • Products
  • Sotio a.s.
    • Table 10-41: Sotio Corporate Summary
    • Company Summary
    • Products
  • Spark Therapeutics
    • Table 10-42: Spark Therapeutics Corporate Summary
    • Company Summary
    • Products
    • Pipeline Projects
  • uniQure N.V.
    • Table 10-43: uniQure Corporate Summary
    • Company Summary
    • Products
  • Vericel Corporation
    • Table 10-44: Vericel Corporate Summary
    • Company Summary
    • Products